T/CACM 1116-2018 Guidelines for the Practice of Preventive Medicine in Traditional Chinese Medicine: People Prone to Blood Stasis-related Diseases
T/CACM 1116-2018
Basic Information
Scope
Main technical content: The revised "Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults" (2016 Edition) issued by the Joint Revision Committee of the Guidelines points out that dyslipidemia typically refers to elevated levels of cholesterol and/or triglycerides (TG) in serum, commonly known as hyperlipidemia. It also notes that the overall prevalence of dyslipidemia in Chinese adults has reached 40.40%, showing a significant increase compared with 2002, indicating that the burden of dyslipidemia and related diseases will continue to increase in the future. Therefore, it is crucial to identify high-risk groups for dyslipidemia and implement standardized prevention and treatment measures. This guideline primarily targets high-risk groups for dyslipidemia, elaborating on their scope, definition, clinical diagnosis, treatment, and recommendations, with the aim of providing guidance for clinicians in their daily work, improving the quality of life for high-risk groups, and reducing the incidence of hyperlipidemia. Based on literature research, this guideline reviews domestic and international intervention literature from ancient and modern perspectives to provide standardized guidance from a practical perspective. The guideline features the following characteristics: ① Integrating aspects such as TCM pathogenesis, syndrome differentiation, and constitution identification to reflect TCM characteristics. ② Emphasizing patient self-assessment and self-care under physician guidance. ③ Combining literature research with evidence-based recommendations of different levels. ④ Integrating literature research and expert opinions to provide evidence-based guidance for the guideline content. It should be noted that this guideline is a recommendatory standard aimed at assisting clinicians or health managers in intervening for high-risk groups for dyslipidemia. As research on these groups deepens, new evidence will emerge, and the guideline will be